relapse or advanced non-small cell lung cancer
Conditions
Interventions
Blood samples will be collected before the first cycle of pembrolizumab administration, at the end of administration, 2 hours after the start of administration, 6 hours after the start of administrati
Sponsors
National Cancer Center Hospital, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients (adults 18 years and older) with histologically or cytologically diagnosed NSCLC 2)Patients with either of the following. (1) Patients who are scheduled to receive treatment with pembrolizumab (either 200 mg or 400 mg as a single agent or in combination with chemotherapy). (2) Patients who are already receiving pembrolizumab treatment (200 mg) and are considering switching to 400 mg. 3)Patients who have given written consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Patients who cannot give consent for specimen collection. 2) Patients who are judged by the principal investigator or the physician in charge to be inappropriate as subjects for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics analysis of pembrolizumab | — |
Countries
Japan
Contacts
Public ContactTatsuya Yoshida
National Cancer Center Hospital, Japan Department of Thoracic Oncology
Outcome results
None listed